Erythropoietic Drive is the Strongest Predictor of Hepcidin Level in Adults with Sickle Cell Disease

Overview

Journal Blood Cells Mol Dis

Specialty Hematology

Date 2015 Oct 14

PMID 26460251

Citations 14

Authors

Matthew S Karafin

Kathryn L Koch

Amy B Rankin

Debora Nischik

Ghady Rahhal

Pippa Simpson

Joshua J Field

Affiliations

Soon will be listed here.

Abstract

Levels of hepcidin, a key modulator of iron metabolism, are influenced by erythropoiesis, iron, and inflammation, all of which may be increased in patients with sickle cell disease (SCD). The objectives of this study were to determine: 1) the variation in hepcidin level, and 2) the relative contribution of erythropoietic drive, iron, and inflammation to differences in hepcidin level in an adult cohort with SCD. In a prospective study, cross-sectional measurements of hepcidin, reticulocyte percentage, erythropoietin, ferritin, and high-sensitivity CRP were obtained. A regression tree analysis was used to measure the association between these interacting factors and hepcidin level. The cohort was comprised of 40 adults with SCD. Median age was 26years, 68% were female, and all had HbSS. Hepcidin values ranged from 30ng/ml to 326ng/ml, with a median of 87ng/ml. Regression tree analysis demonstrated that reticulocyte percentage, erythropoietin, ferritin and hs-CRP all were associated with hepcidin. The highest hepcidin values were found in subjects with low reticulocyte percentage and erythropoietin. In conclusion, erythropoietic drive, iron status, and inflammation all contribute to variation in hepcidin level. The strongest contributor is erythropoietic drive. Future studies could determine whether suppression of erythropoiesis with chronic transfusion influences hepcidin level.

Citing Articles

Ferroptosis as an emerging target in sickle cell disease.

Fortuna V, Lima J, Oliveira G, Oliveira Y, Getachew B, Nekhai S Curr Res Toxicol. 2024; 7:100181.

PMID: 39021403 PMC: 11252799. DOI: 10.1016/j.crtox.2024.100181.

The role of MRI-R2* in the detection of subclinical pancreatic iron loading among transfusion-dependent sickle cell disease patients and correlation with hepatic and cardiac iron loading.

Raief Mosaad B, Ibrahim A, Mansour M, Elalfy M, Ebeid F, Abdeldayem E Insights Imaging. 2022; 13(1):140.

PMID: 36057708 PMC: 9440968. DOI: 10.1186/s13244-022-01280-x.

Vasculo-toxic and pro-inflammatory action of unbound haemoglobin, haem and iron in transfusion-dependent patients with haemolytic anaemias.

Vinchi F, Sparla R, Passos S, Sharma R, Vance S, Zreid H Br J Haematol. 2021; 193(3):637-658.

PMID: 33723861 PMC: 8252605. DOI: 10.1111/bjh.17361.

The Interplay between Drivers of Erythropoiesis and Iron Homeostasis in Rare Hereditary Anemias: Tipping the Balance.

Grootendorst S, de Wilde J, van Dooijeweert B, van Vuren A, van Solinge W, Schutgens R Int J Mol Sci. 2021; 22(4).

PMID: 33672223 PMC: 7927117. DOI: 10.3390/ijms22042204.

Iron homeostasis in a mouse model of thalassemia intermedia is altered between adolescence and adulthood.

Sanyear C, Butthep P, Eamsaard W, Fucharoen S, Svasti S, Masaratana P PeerJ. 2020; 8:e8802.

PMID: 32219031 PMC: 7085893. DOI: 10.7717/peerj.8802.

References

Ramos E, Kautz L, Rodriguez R, Hansen M, Gabayan V, Ginzburg Y . Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology. 2011; 53(4):1333-41. PMC: 3074982. DOI: 10.1002/hep.24178. View

Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G . Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007; 92(5):583-8. DOI: 10.3324/haematol.10842. View

Ginzburg Y, Rivella S . β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood. 2011; 118(16):4321-30. PMC: 3204905. DOI: 10.1182/blood-2011-03-283614. View

Vichinsky E, Butensky E, Fung E, Hudes M, Theil E, Ferrell L . Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol. 2005; 80(1):70-4. DOI: 10.1002/ajh.20402. View

Wood J, Michael Tyszka J, Carson S, Nelson M, Coates T . Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2003; 103(5):1934-6. DOI: 10.1182/blood-2003-06-1919. View

Walter P, Fung E, Killilea D, Jiang Q, Hudes M, Madden J . Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006; 135(2):254-63. PMC: 2185791. DOI: 10.1111/j.1365-2141.2006.06277.x. View

Mariani R, Trombini P, Pozzi M, Piperno A . Iron metabolism in thalassemia and sickle cell disease. Mediterr J Hematol Infect Dis. 2011; 1(1):e2009006. PMC: 3033158. DOI: 10.4084/MJHID.2009.006. View

Ezeh C, Ugochukwu C, Weinstein J, Okpala I . Hepcidin, haemoglobin and ferritin levels in sickle cell anaemia. Eur J Haematol. 2004; 74(1):86-8. DOI: 10.1111/j.1600-0609.2004.00337.x. View

Pak M, Lopez M, Gabayan V, Ganz T, Rivera S . Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006; 108(12):3730-5. PMC: 1895477. DOI: 10.1182/blood-2006-06-028787. View

10.

Huang H, Constante M, Layoun A, Santos M . Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli. Blood. 2009; 113(15):3593-9. PMC: 2891008. DOI: 10.1182/blood-2008-08-173641. View

11.

Ballas S . Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol. 2001; 38(1 Suppl 1):30-6. DOI: 10.1016/s0037-1963(01)90058-7. View

12.

Ghoti H, Fibach E, Westerman M, Gordana O, Ganz T, Rachmilewitz E . Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome. Br J Haematol. 2011; 153(1):118-20. DOI: 10.1111/j.1365-2141.2011.08587.x. View

13.

Pasricha S, Frazer D, Bowden D, Anderson G . Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Blood. 2013; 122(1):124-33. DOI: 10.1182/blood-2012-12-471441. View

14.

Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen B . IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113(9):1271-6. PMC: 398432. DOI: 10.1172/JCI20945. View

15.

Voskaridou E, Douskou M, Terpos E, Papassotiriou I, Stamoulakatou A, Ourailidis A . Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol. 2004; 126(5):736-42. DOI: 10.1111/j.1365-2141.2004.05104.x. View

16.

Ghoti H, Goitein O, Koren A, Levin C, Kushnir T, Rachmilewitz E . No evidence for myocardial iron overload and free iron species in multitransfused patients with sickle/beta-thalassaemia. Eur J Haematol. 2009; 84(1):59-63. DOI: 10.1111/j.1600-0609.2009.01355.x. View

17.

Ganz T, Nemeth E . Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012; 1823(9):1434-43. PMC: 4048856. DOI: 10.1016/j.bbamcr.2012.01.014. View

18.

Gardenghi S, Marongiu M, Ramos P, Guy E, Breda L, Chadburn A . Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 2007; 109(11):5027-35. PMC: 1885515. DOI: 10.1182/blood-2006-09-048868. View

19.

Kearney S, Nemeth E, Neufeld E, Thapa D, Ganz T, Weinstein D . Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer. 2005; 48(1):57-63. DOI: 10.1002/pbc.20616. View

20.

Darbari D, Kple-Faget P, Kwagyan J, Rana S, Gordeuk V, Castro O . Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006; 81(11):858-63. DOI: 10.1002/ajh.20685. View